Enhancement of the liver and pancreas in the hepatic arterial dominant phase: Comparison of hepatocyte‐specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 tesla MRI in the same patient

Abstract

The 0.05 mmol/kg gadobenate dimeglumine-enhanced abdominal MRI studies at 3T and 1.5T MR systems are superior in relative enhancement of the liver in HADP to 0.025 mmol/kg gadoxetic acid-enhanced MRI. This type of assessment may provide comparative effectiveness data.